Protein formulations with reduced viscosity and uses thereof
Protein formulations and methods for reducing the viscosity of a protein formulation are provided. The method for reducing the viscosity of a protein formulation comprises adding a viscosity reducing agent, such as calcium chloride or magnesium chloride to the protein formulation.
1. A reduced viscosity formulation, comprising:
(i) an antibody or an antigen binding fragment thereof;
(ii) magnesium chloride at a concentration of between about 0.5 mM and about 25 mM in the formulation; and
(iii) a buffer;
wherein the pH of the formulation is about 5.5 to about 6.5.
2. The reduced viscosity formulation of claim 1 , further comprises at least one of an antioxidant, a surfactant, and a cryoprotectant.
3. The reduced viscosity formulation of claim 1 , wherein the antibody is an anti-myostatin antibody.
4. The reduced viscosity formulation of claim 3 , wherein the anti-myostatin antibody is MYO-022, MYO-028, or MYO-029.
5. The reduced viscosity formulation of claim 1 , wherein the antibody is an anti-IL-12 antibody.
6. The reduced viscosity formulation of claim 5 , wherein the anti-IL-12 antibody is J695.
7. The reduced viscosity formulation of claim 1 , wherein the antibody is an anti-IL-13 antibody.
8. The reduced viscosity formulation of claim 7 , wherein the anti-IL-13 antibody is IMA-638.
9. The reduced viscosity formulation of claim 1 , wherein magnesium chloride is at a concentration of about 1 mM in the formulation.
10. The reduced viscosity formulation of claim 1 , wherein the magnesium chloride is at a concentration of about 2.5 mM in the formulation.
11. The reduced viscosity formulation of claim 1 , wherein the magnesium chloride is at a concentration of about 5 mM in the formulation.
12. The reduced viscosity formulation of claim 1 , wherein the magnesium chloride is at a concentration of about 10 mM in the formulation.
13. The reduced viscosity formulation of claim 1 , wherein the magnesium chloride is at a concentration of about 15 mM in the formulation.
14. The reduced viscosity formulation of claim 1 , wherein the magnesium chloride is at a concentration of about 20 mM in the formulation.
15. The reduced viscosity formulation of claim 1 , wherein the magnesium chloride is at a concentration of about 25 mM in the formulation.
16. The reduced viscosity formulation of claim 1 , wherein the buffer is histidine buffer.
17. The reduced viscosity formulation of claim 16 , wherein the histidine buffer is at a concentration of about 4 mM: to about 60 mM.
18. The reduced viscosity formulation of claim 1 , wherein the pH of the formulation is 6.0.
19. A reduced viscosity formulation, comprising:
(i) an antibody or an antigen binding fragment thereof, wherein the antibody is selected from the group consisting of an anti-myostatin antibody, an IL-12 antibody, an IL-13 antibody, and a combination thereof;
(ii) a viscosity reducing agent at a concentration of between about 0.5 mM and about 25 mM in the formulation, wherein the viscosity reducing agent is calcium chloride or magnesium chloride; and
(iii) a buffer;
wherein the pH of the reduced viscosity formulation is about 5.5 to about 6.5.